图片发自160App
全球首个“AI科学家天团”FutureHouse 展现强大实力，仅用2.5个月就研发出治盲AI新药。该团队由四大AI智能体（Crow、Falcon、Owl、Phoenix ）组成，全程主导研发，人类仅辅助打杂。AI智能体包办假设生成、实验设计、数据分析等，还发现用于青光眼治疗的Ripasudil可作干性老年性黄斑变性（dAMD，致盲主因之一 ）候选药，展现AI驱动科学发现的全新范式，为医药研发带来变革，后续若经人体试验验证，有望改写治盲格局 。
图片发自160App
图片发自160App
图片发自160App
图片发自160App
图片发自160App
图片发自160App
图片发自160App
The world's first "AI Scientist Dream Team" - FutureHouse - has demonstrated remarkable capabilities, developing a blindness - treating AI - based new drug in just 2.5 months. Composed of four major AI agents (Crow, Falcon, Owl, and Phoenix), the team led the entire R & D process, with humans only providing auxiliary support. The AI agents handled everything from hypothesis generation, experimental design to data analysis. They even discovered that Ripasudil, previously used for glaucoma treatment, can be a candidate drug for dry age - related macular degeneration (dAMD, one of the main causes of blindness). This showcases a new paradigm of AI - driven scientific discovery, bringing transformation to pharmaceutical R & D. If verified by human trials in the future, it is expected to rewrite the pattern of blindness treatment.
